# Marimed Inc.: overview MRMD · OTC · CIK 1522767 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mrmd.md) · [Financials](/companies/mrmd/financials.md) · [Filings](/companies/mrmd/filings.md) · [Insiders](/companies/mrmd/insiders.md) Latest reported revenue: [$41.9m](/filings/0001522767-26-000167.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001522767-26-000167). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [40.6](/filings/0001522767-25-000224.md) | [38.9 d](/filings/0001522767-26-000030.md) | [37.9](/filings/0001522767-26-000073.md) | [39.5](/filings/0001522767-26-000167.md) | [40.8](/filings/0001522767-25-000224.md) | [41.7 d](/filings/0001522767-26-000030.md) | [39.5](/filings/0001522767-26-000073.md) | [41.9](/filings/0001522767-26-000167.md) | | Gross margin | % | [41.3%](/filings/0001522767-25-000224.md) | [32.5% d](/filings/0001522767-26-000030.md) | [39.8%](/filings/0001522767-26-000073.md) | [40.3%](/filings/0001522767-26-000167.md) | [40.1%](/filings/0001522767-25-000224.md) | [25.2% d](/filings/0001522767-26-000030.md) | [38.7%](/filings/0001522767-26-000073.md) | [38.7%](/filings/0001522767-26-000167.md) | | Operating margin | % | [3.3%](/filings/0001522767-25-000224.md) | [(3.8%) d](/filings/0001522767-26-000030.md) | [(2.4%)](/filings/0001522767-26-000073.md) | [2.6%](/filings/0001522767-26-000167.md) | [3.9%](/filings/0001522767-25-000224.md) | [(10.9%) d](/filings/0001522767-26-000030.md) | [0.3%](/filings/0001522767-26-000073.md) | [1.0%](/filings/0001522767-26-000167.md) | | Net margin | % | [(2.5%)](/filings/0001522767-25-000224.md) | [(21.2%) d](/filings/0001522767-26-000030.md) | [(14.5%)](/filings/0001522767-26-000073.md) | [(3.5%)](/filings/0001522767-26-000167.md) | [(7.2%)](/filings/0001522767-25-000224.md) | [(11.1%) d](/filings/0001522767-26-000030.md) | [(9.6%)](/filings/0001522767-26-000073.md) | [(8.6%)](/filings/0001522767-26-000167.md) | | Diluted EPS | $ per share | [0.00](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [0.00](/filings/0001522767-26-000167.md) | [(0.01)](/filings/0001522767-25-000224.md) | not reported | [(0.01)](/filings/0001522767-26-000073.md) | [(0.01)](/filings/0001522767-26-000167.md) | | Free cash flow | $m | [(1.8) d](/filings/0001522767-25-000224.md) | [(1.5) d](/filings/0001522767-26-000030.md) | [1.0](/filings/0001522767-26-000073.md) | [(0.0) d](/filings/0001522767-26-000167.md) | [2.1 d](/filings/0001522767-25-000224.md) | [3.4 d](/filings/0001522767-26-000030.md) | [0.6](/filings/0001522767-26-000073.md) | [1.9 d](/filings/0001522767-26-000167.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [121](/filings/0001522767-23-000015.md) | [134](/filings/0001522767-24-000007.md) | [149](/filings/0001522767-25-000014.md) | [158](/filings/0001522767-26-000030.md) | [160](/filings/0001522767-26-000030.md) | | Gross margin | % | [54.6%](/filings/0001522767-23-000015.md) | [47.7%](/filings/0001522767-24-000007.md) | [44.4%](/filings/0001522767-25-000014.md) | [39.7%](/filings/0001522767-26-000030.md) | [36.2%](/filings/0001522767-26-000030.md) | | Operating margin | % | [22.1%](/filings/0001522767-23-000015.md) | [15.2%](/filings/0001522767-24-000007.md) | [9.7%](/filings/0001522767-25-000014.md) | [1.7%](/filings/0001522767-26-000030.md) | [(1.8%)](/filings/0001522767-26-000030.md) | | Net margin | % | [5.9%](/filings/0001522767-23-000015.md) | [10.0%](/filings/0001522767-24-000007.md) | [(10.8%)](/filings/0001522767-25-000014.md) | [(7.9%)](/filings/0001522767-26-000030.md) | [(9.1%)](/filings/0001522767-26-000030.md) | | Diluted EPS | $ per share | [0.02](/filings/0001522767-23-000015.md) | [0.04](/filings/0001522767-24-000007.md) | [(0.04)](/filings/0001522767-25-000014.md) | [(0.03)](/filings/0001522767-26-000030.md) | [(0.04)](/filings/0001522767-26-000030.md) | | Free cash flow | $m | [18.0](/filings/0001522767-23-000015.md) | [(4.8)](/filings/0001522767-24-000007.md) | [(12.2)](/filings/0001522767-25-000014.md) | [(5.2)](/filings/0001522767-26-000030.md) | [6.5](/filings/0001522767-26-000030.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mrmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Canton Hathaway, LLC](/funds/1755785.md) | 2026-06-30 | $45.2k | 645,100 | | Unchanged | | [Game Plan Financial Advisors, LLC](/funds/1802952.md) | 2026-06-30 | $7 | 100 | | Unchanged | ## Recent filings [All 377 filings](/companies/mrmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:13 ET | [8-K](/filings/0001522767-26-000213.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001522767-26-000213 | | 2026-09-23 | 16:05 ET | [8-K](/filings/0001522767-26-000188.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001522767-26-000188 | | 2026-09-22 | 16:42 ET | [DEF 14A](/filings/0001522767-26-000183.md) | Proxy statement, period 2026-10-28 | 0001522767-26-000183 | | 2026-08-13 | 16:11 ET | [10-Q](/filings/0001522767-26-000167.md) | Quarterly report, period 2026-06-30 | 0001522767-26-000167 | | 2026-08-12 | 17:07 ET | [8-K](/filings/0001522767-26-000164.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001522767-26-000164 | | 2026-06-08 | 16:18 ET | [8-K](/filings/0001522767-26-000107.md) | 5.07 Shareholder vote results | 0001522767-26-000107 | | 2026-05-14 | 16:19 ET | [10-Q](/filings/0001522767-26-000073.md) | Quarterly report, period 2026-03-31 | 0001522767-26-000073 | | 2026-05-13 | 17:13 ET | [8-K](/filings/0001522767-26-000070.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001522767-26-000070 | | 2026-04-23 | 16:06 ET | [DEF 14A](/filings/0001522767-26-000058.md) | Proxy statement, period 2026-06-04 | 0001522767-26-000058 | | 2026-03-12 | 16:08 ET | [10-K](/filings/0001522767-26-000030.md) | Annual report, period 2025-12-31 | 0001522767-26-000030 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001522767-26-000030.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/41fdcbcb-1691-4c98-98c8-d645324b076a) ## About the filer - CIK: 1522767 - Tickers: MRMD - Exchange: OTC - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:14 ET. No prices; not investment advice.